Pure Global
NCT05941910

The Effect of Coenzyme Q10 on Endothelial, Vascular and Myocardial Function

The Effect of 6-month Treatment With Coenzyme Q10 on Endothelial, Vascular and Myocardial Function in Patients With Non-alcoholic Fatty Liver Disease
Attikon Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Non-Alcoholic Fatty Liver Disease
Drug/Device/Intervention
Q10
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Attikon Hospital
Location
Athens, Greece
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2023
End date
Dec 31, 2023
Enrollment
60 participants
Primary outcome

The effect of Q10 on Left Ventricular Myocardial Function

Summary

Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk.
 The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial,
 vascular and myocardial function in patients with NAFLD

ICD-10 classifications
Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05941910
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05941910 through Pure Global AI's free database. This Phase 2 trial is sponsored by Attikon Hospital and is currently Recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.